H.C. Wainwright Is Bullish on Relay Therapeutics, Inc. (RLAY)

Why It Matters

The breakthrough designation and strong early efficacy data could accelerate market entry and lift the stock’s upside, while a robust cash runway lowers financing risk for shareholders.

Key Takeaways

• Price target lifted to $25, maintaining Buy rating.
• FDA Breakthrough Therapy for zovegalisib‑fulvestrant in PIK3CA‑mutant breast cancer.
• Phase 1 triplet shows 44% response, Phase 3 slated for early 2027.
• Cash balance up to $642 million, funding through 2029.
• Partnership with Pfizer adds credibility to atiraciclib combo.

Pulse Analysis

Relay Therapeutics leverages a protein‑motion‑focused platform to design small‑molecule inhibitors, a strategy that differentiates it from traditional biotech pipelines. The recent FDA Breakthrough Therapy designation for zovegalisib combined with fulvestrant targets a genetically defined subset of HR+/HER2‑negative breast cancer, a market valued at several billion dollars. Early Phase 1/2 data showing 11.1 months of median progression‑free survival and comparable efficacy across kinase variants suggest the drug could fill an unmet need for patients who have exhausted endocrine options.

Financially, Relay’s cash pile rose to $642.1 million, up from $554.5 million a year earlier, extending its liquidity runway to 2029 without additional equity raises. This balance sheet strength is rare among mid‑stage oncology firms, many of which rely on frequent financing rounds that dilute existing shareholders. The cash cushion not only supports the upcoming Phase 3 trial but also provides flexibility for potential M&A activity or strategic collaborations, enhancing the company’s valuation metrics relative to peers that are cash‑constrained.

Looking ahead, the Phase 3 trial slated for early 2027, co‑developed with Pfizer’s atiraciclib, could be a catalyst for significant market re‑rating if the triplet replicates the 44% objective response observed in early‑stage patients. Investors will watch enrollment speed, regulatory milestones, and competitive dynamics in the PI3K‑mutant breast cancer space. Should the trial succeed, Relay could transition from a cash‑burning R&D play to a revenue‑generating biotech, positioning it for broader institutional interest and potentially higher price targets.